SGLT2 inhibitors and GLP-1 agonists are class 1 medications, but many Medicaid patients have challenges with access.

In patients with T2D who had been hospitalized for poorly controlled blood glucose, SGLT2 inhibitors nearly doubled the risk ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

A new weight loss drug that's being trialled as a daily pill and could rival Ozempic has delivered some astonishing results.

BLOCKBUSTER ‘Ozempic-style’ fat jabs could increase the risk of depression and suicidal thoughts, experts have warned. The ...

Experts express alarm that GLP-1 RAs may trigger or worsen eating disorders. But is there any role they might play in binge ...

Blockbuster weight loss drugs like Ozempic could leave users at a higher risk of depression and suicidal thoughts, a ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...

US President Donald Trump’s recent weight loss has become the talk of the town after his recent medical exam revealed a ...

GLP-1 receptor agonists such as semaglutide and tirzepatide have proven to be highly effective in supporting weight loss by regulating appetite and metabolism. These medications work by mimicking ...